title: Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
authors.forename: Parvin
authors.initials: P
authors.lastname: Adimi
authors.forename: Flemming
authors.initials: F
authors.lastname: Hansen
authors.forename: Mogens
authors.initials: M
authors.lastname: Kjaer
authors.forename: Kristian
authors.initials: K
authors.lastname: Aabo
authors.forename: Nina
authors.initials: N
authors.lastname: Keldsen
authors.forename: Per
authors.initials: P
authors.lastname: Pfeiffer
authors.forename: Erik
authors.initials: E
authors.lastname: Sandberg
authors.forename: Anders
authors.initials: A
authors.lastname: Jakobsen
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000139:chemically induced; D004338:Drug Combinations; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009325:Nausea / Q000139:chemically induced; D015996:Survival Rate; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil